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Abstract
The observation showing that Lewy type synucleinopathy (LTS), the pathological hallmark of Parkinson’s disease
(PD), is found in the gut of almost all PD subjects led to a substantial amount of research to develop a diagnostic
procedure in living patients based on endoscopically obtained gastrointestinal biopsies. However, the existing
studies have provided conflicting results regarding the sensitivity and specificity of gastrointestinal biopsies for the
detection of LTS. We therefore undertook a multi-center staining and blinded judging of a common set of
slides from colonic biopsies to determine the optimal protocol for the detection of LTS. Four different
immunohistochemical methods, developed in four separate expert laboratories, were evaluated for their
sensitivity and specificity to detect enteric LTS. Test sets of formalin-fixed, paraffin-embedded sections from
biopsies of 9 PD subjects and 3 controls were stained with the 4 methods and graded by 4 different
observers. Four types of staining morphology (granular staining in the lamina propria, perivascular/vascular
wall staining in the submucosa, lacy-granular pattern in the submucosa and epithelial cell nuclear staining)
were variably observed in the slides stained by the 4 methods. Positive alpha-synuclein staining was observed
by all 5 judges in most of the slides from control cases, regardless of the staining methods that were used.
Moreover, none of the tested method or staining pattern had a specificity and sensitivity more than 80 %
regarding to PD. Overall, our study suggest that the tested methods are not adequate for the prediction of
PD using gastrointestinal biopsies. Future studies are warranted to test new immunostaining methods.
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Introduction
Since the discovery of aggregated and phosphorylated
alpha-synuclein as the primary component of Lewy
pathology, immunohistochemistry for alpha-synuclein
has become the histological technique of choice for the
diagnosis of Parkinson’s disease (PD) [1, 2]. Several aut-
opsy studies, showed that the distribution of Lewy-type
synucleinopathy (LTS) is much greater than formerly ap-
preciated extending to peripheral autonomic neuronal
circuits [2, 3]. The presence of LTS in peripheral
neuronal tissues accessible to biopsies provides new op-
portunities for the development of original biomarkers
that will directly assess the pathological process in living
patients [4, 5]. Among these peripheral autonomic neur-
onal circuits, the enteric nervous system displays several
specific features that make it a prime candidate tissue
for being a histopathological marker of PD as (i) it is an
integrative neuronal network whose organization and
complexity closely resemble that of the central nervous
system (ii) it has been shown to be affected by the
pathological process in the vast majority of PD patients
[3, 6–9] (iii) it is readily, repeatedly and safely accessible
by endoscopic biopsies in living patients [10, 11]. This
logically led laboratories to develop specific methods for
* Correspondence: derkinderenp@yahoo.fr
1Inserm, U913, Nantes F-44035, France
2Nantes University, Nantes F-44035, France
Full list of author information is available at the end of the article
© 2016 Corbillé et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Corbillé et al. Acta Neuropathologica Communications  (2016) 4:35 
DOI 10.1186/s40478-016-0305-8
the detection of LTS in routine gastrointestinal biopsies.
However, the diversity of methodology between studies,
especially regarding the immunohistochemical methods
used, has led to conflicting results and discrepancies re-
garding the sensitivity and specificity of gastrointestinal
biopsies for the detection of LTS [12–17]. The aim of
our research project was therefore to test several differ-
ent immunohistochemical methods for the detection of
LTS in colonic biopsy with the objective of identifying a
highly sensitive and specific technique that might be
widely and readily used in different laboratories. For this
purpose, a panel of expert investigators have participated,
based on their published work using alpha-synuclein im-
munohistochemistry [2, 13, 18, 19] and were asked to
stain identical sets of paraffin-embedded sections from co-
lonic biopsies with their own optimized method.
Materials and methods
Selection of subjects and formalin-fixed paraffin-embedded
blocks
Nine PD patients were included in this study, chosen
from among 29 subjects that had been recruited from
the movement disorder clinic in Nantes University
Hospital, France for a previously published study of enteric
synucleinopathy in wholemount mucosal-submucosal bi-
opsies [12]. From the same study, a set of 3 subjects (out of
10 in the original study) requiring a total colonoscopy for
colorectal cancer screening were included as controls. The
clinical characteristics of study subjects are summarized in
Table 1.
The 3 control and 9 PD subjects were chosen after
screening sections from their archived descending colon
biopsies stored in formalin-fixed, paraffin-embedded
(FFPE) blocks. Screening was performed by AGC and FL
of the Neuropathology Laboratory in Angers, France.
Tissue blocks were fixed in 10 % (v/v) formalin for 48 h,
embedded in paraffin and cut at 4 μm using a Leica
RM125 microtome. Sections were collected on slides
(Superfrost Plus, VWR, Fontenay sous Bois, France) and
stained with an immunoperoxidase method for the de-
tection of phosphorylated alpha-synuclein (Table 2).
Global grading of all staining, regardless of morphology,
was assigned using a 0–3 semi-quantitative density scale.
PD cases were divided into 3 groups with 3 subjects in
each group, one group with sparse staining density (PD
group 0), one with moderate staining density (PD group
1) and one with high staining density (PD group 2). Con-
trol subjects had minimal staining densities (Table 1).
None of the control subjects had a history of neuro-
logical or psychiatric diseases, none had abnormalities
on neurological examination and on telephone inter-
views done in 2014 none had subsequently developed
parkinsonian signs or symptoms. The study protocol
was approved by the local Committee on Ethics and
Human Research (Comité de Protection des Personnes
Ouest VI), and registered on ClinicalTrials.gov (identifier
NCT00491062). Written informed consent was obtained
from each patient and from each normal volunteer.
Preparation of test slides and distribution to participating
labs
The design of the study is depicted diagrammatically in
Fig. 1. Four unstained sections (4 μm) from each block
(each block containing one biopsy tissue fragment) were
sent by the central laboratory (AGC and PD) along with
a brief methods section describing how the tissue was
sampled to the 3 other participating testing laboratories
(48 slides per lab, 144 slides in all). Each participating
lab (TB, DM and JK) including the central laboratory
stained the full set of sections with their optimal immu-
noperoxidase method for enteric synucleinopathy
(Table 2). Blocks were assigned a number from 1–12
using a random number generator in order to blind eval-
uators to diagnosis.
Slides grading and statistical analysis
The stained slide sets were initially examined by TB,
who then constructed four different semi-quantitative
grading templates (Fig. 2 and Additional file 1: Figures
S1 and S2) with associated scoring tables for each of the
four major morphological staining types present. The
four different staining patterns were: (1) granular stain-
ing in the lamina propria of the mucosa (2) perivascu-
lar/vascular wall staining with a fine dotted pattern, in
the submucosa (3) lacy-granular pattern in the sub-
mucosa (4) epithelial cell nuclear staining. The photomi-
crographs in Fig. 2 illustrate each staining pattern. As
some of the staining patterns (types 2 and 3) were
present only in the submucosa, or depended on the
presence of blood vessels in the submucosa, the
Table 1 Clinical and pathological characteristics of study subjects
Diagnosis Age Mean (range) Gender M:F Disease duration (y)
mean (range)
Wholemount synucleinopathy
density grade mean (range)
FFPE synucleinopathy density
grade mean (range)
Control (n = 3) 64 (61–68) 2:1 N/A 0 0
PD (n = 9) 66 (47–71) 8:1 12.2 (4–20) 1.6 (0–2) 1.9 (0.5–3)
Presumptive synucleinopathy in the formalin-fixed, paraffin-embedded (FFPE) sections was graded on a 0–3 scale. Wholemount synucleinopathy scores shown are
from the original published study [12] and were graded as 0–2 based on the number of positive biopsies out of the 4 that were taken from each subject (the
maximum assigned score was 2)
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presence or absence of submucosa or blood vessels was
recorded for each biopsy. No assumptions were made as
to whether any of the staining patterns seen might rep-
resent specific or non-specific staining of pathological
alpha-synuclein deposits, and all slides were graded for
each pattern by each participating test lab in turn (TB,
JK, and DM and one additional judge: John Lee, MD,
PhD, of the Department of Pathology, NorthShore
University Health System, Evanston, IL). The slides as
well as the scoring tables were then returned to PD at
the central laboratory. Density scores of none, sparse,
moderate and frequent were converted to numerical
values (0–4) for statistical analysis. Sum and average
score per biopsy were calculated. All labs submitted
their grading to the project principal investigator and re-
sults were analyzed after unblinding.
Statistical analyses were performed using intraclass
correlation coefficient for judge ratings of staining dens-
ities, for each laboratory (TB, JK, FL, DM) and staining
template pattern (LP = lamina propria granular pattern;
EC = endothelial cell nuclear pattern; LG = lacy-granular
pattern; PV = perivascular-vascular pattern) were de-
termined. The diagnostic accuracy of each staining
pattern, in terms of being able to predict a diagnosis
Table 2 Immunoperoxidase methods used by the central laboratory (AGC/FL) and the three testing laboratories
Primary antibody Epitope exposure Signal development
AGC/FL (Angers, France) p-synuclein, #64
WAKO, Osaka
1:30,000









37 ° C, 20 min
ABC, DAB
Vector Laboratories
JK (Chicago, IL) Alpha-synuclein, LB509
Invitrogen
1:500








72 ° C, 8 min
Citrate buffer, pH 6 4
90 ° C, 4 min
Ventana Benchmark Ultra,
Optiview multimer and amplifier
p-synuclein = alpha-synuclein phosphorylated at serine 129; ABC = avidin-biotin peroxidase complex; DAB = 3, 3’ di-aminobenzidine
Fig. 1 Design of the study
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of PD, was calculated from each individual judge’s results
and for the average of all judge’s results, for all applicable
staining patterns seen on slides from each testing labora-
tory as well as from the central laboratory.
Results
LTS staining pattern and density scores
The density scores of the 4 raters were averaged to ob-
tain a mean score of LTS staining per biopsy. Figure 3
represents the mean of density score by groups (controls
and PD groups) for each staining pattern. Additional file
1: Table S1 shows the results of individual judge scores
for the staining done by each test laboratory as well as
by the central laboratory, for each scoring template. The
four types of staining morphology were variably present
in the slides stained by the 4 methods. The granular
lamina propria staining was seen to some extent in all
slide sets. The perivascular-vascular pattern was seen
in slides stained by two of the labs (DM, AGC/FL).
The submucosa lacy-granular pattern was seen only
in slides stained by one lab (JK). The epithelial cell
nuclear staining pattern was seen in slides stained by
two labs (TB, AGC/FL).
Interobserver reliability and intraclass correlation
coefficient
Interobserver reliability was generally moderately ac-
ceptable except for some staining morphology types
in two laboratories (TB and AGC/FL, Table 3).
Judge’s results were excluded when submucosa was
not present, for those staining morphologies dependent
on the presence of submucosa (DM-PV, JK, AGC/
FL-PV). Submucosa was not present in 6 out of 48
slides.
Intraclass correlation coefficient for judge ratings of
staining densities, for each laboratory and staining
morphology type is shown in Table 3. Some judges
did not rate some staining patterns for some labora-
tories. Results are therefore given for four judges
where all judge scores were available and for the
three common judges when one or more judge scores
were missing. Cases without submucosa in the slide
were excluded from results for staining morphologies
Fig. 2 Photomicrographs of LTS immunostaining in colonic biopsies sections, illustrating the 4 staining patterns that were graded. a lamina
propria granular pattern, Template 1; b perivascular/vascular pattern, Template 2; c lacy-granular pattern, Template 3; d epithelial nuclear pattern,
Template 4. Scale bar: 50 μM
Fig. 3 LTS immunostaining scores for each template. Bar graph represents the LTS mean score for each group for each template in all methods.
Data correspond to mean ± SEM of the 3 cases per group. PD group 0, 1 and 2 correspond to PD cases with sparse, moderate and high presumed LTS
staining. Note that some templates were not observed in some methods. Template 1 : lamina propria granular pattern; Template 2 : perivascular/
vascular pattern; Template 3: lacy-granular pattern; Template 4 : epithelial nuclear pattern
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dependent on the presence of submucosa (DM-PV,
AGC/FL-PV, JK-LG).
Diagnostic accuracy for identifying PD cases, of judge
ratings of staining densities, for each laboratory and
staining morphology type were calculated (Table 4).
Cases without submucosa in the slide were excluded
from results for staining morphologies. Sensitivity were
often acceptable (>80 %) but specificity too weak. None
of the tested method or staining pattern had a specificity
and sensitivity more than 80 % regarding to PD.
Discussion
The primary aim of this study was to evaluate and com-
pare different IHC methods for the detection of LTS in
colonic biopsies. Regarding the ability to discriminate
between control and PD subjects, the overall impression
is that this was not accomplished by any of the staining
methods or morphologically-defined staining types.
One of the striking results of our study is that positive
alpha-synuclein staining was observed by all 4 judges in
most of the slides from control cases, regardless of the
Table 3 Intraclass correlation coefficient (ICC) for judge ratings of staining densities, for each testing laboratory (DM, TB, JK) and the
central laboratory (AGC/FL), of each staining morphology type (LP = lamina propria granular pattern; EC = epithelial cell nuclear
pattern; LG = lacy-granular pattern; PV = perivascular-vascular pattern)
Box 1 DM-LP Box 2 TB-EC Box 2 TB-LP Box 3 JK-LG Box 3 JK-LGa Box 4 AGC/FL-EC Box 4 AGC/FL-LP Box 4 AGC/FL-PV
n 12 12 12 12 11 12 12 12
Four Raters
ICC 0.73 −0.04 0.02 0.81 0.78 NA 0.53 NA
Three Raters
ICC 0.88 −0.05 0.00 0.79 0.72 0.16 0.78 0.80
Some judges did not rate some staining patterns for some laboratories; results are therefore given for four judges where all judge scores were available and for
the three common judges when one or more judge scores were missing. Cases without submucosa in the slide were excluded from results for staining
morphologies dependent on the presence of submucosa (Box 3, JK-LG)
aExcluding insufficient submucosa
Table 4 Diagnostic accuracy for identifying PD cases, of judge ratings of staining densities, for each laboratory (DM, TB, JK, AGC/FL)
and staining morphology type (LP = lamina propria granular pattern; EC = endothelial cell nuclear pattern; LG = lacy-granular pattern;
PV = perivascular-vascular pattern). Results for the average of judge’s ratings as well as the “best” judge’s ratings are shown. Some
judges did not rate some staining patterns for some laboratories; results are therefore given for four judges where all judge scores
were available and for the three common judges when one or more judge scores were missing. Cases without submucosa in the
slide were excluded from results for staining morphologies dependent on the presence of submucosa (DM-PV, AGC/FL-PV, JK-LG).



















N 12 7 12 12 12 11 12 12 12
Four Raters
AUC 0.63 0.65 NA NA 0.58 0.53 NA 0.67 NA
Sensitivity 86 % 83 % 28 % 28 % 89 % 97 % NA 81 % NA
Specificity 25 % 0 % 75 % 83 % 17 % 17 % NA 33 % NA
Youden Index 0.11 −0.17 0.03 0.11 0.06 0.14 NA 0.14 NA
Three Raters
AUC 0.62 0.53 NA NA 0.58 0.51 0.71 0.67 0.69
Sensitivity 85 % 78 % 37 % 15 % 89 % 100 % 74 % 74 % 70 %
Specificity 33 % 0 % 67 % 100 % 11 % 11 % 56 % 22 % 44 %
Youden Index 0.19 −0.22 0.04 0.15 0.00 0.11 0.30 −0.04 0.15
Best Rater
Rater DM JK JL JL JK DM JL JK DM
AUC 0.61 1.00 0.50 0.72 0.59 0.46 0.83 0.67 0.80
Sensitivity 100 % 100 % 78 % 44 % 89 % 100 % 67 % 100 % 78 %
Specificity 33 % 0 % 33 % 100 % 33 % 33 % 100 % 67 % 67 %
Youden Index 0.33 0.00 0.11 0.44 0.22 0.33 0.67 0.67 0.44
aExcluding insufficient submucosa
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staining methods that were used. Although several stud-
ies showed a high sensitivity of FFPE gastrointestinal bi-
opsies for the detection of LTS in PD patients [13, 15],
recent reports have raised concerns regarding the speci-
ficity of this approach because alpha-synuclein immuno-
reactivity was also observed in some healthy individuals
without PD [17, 20]. This lack of specificity may result
from technical difficulties inherent in the use of FFPE
gastrointestinal biopsies for the detection of alpha-
synuclein. Besides neurons, alpha-synuclein is physiologic-
ally expressed by red blood cells and vascular endothelial
cells [21, 22], two cell types, which can be retrieved from a
routine gastrointestinal biopsy and thus be detected by
alpha-synuclein immunohistochemistry in both healthy
subjects and PD patients. Moreover, the interpretation of
alpha-synuclein immunostaining for the detection of en-
teric LTS in PD can be delicate because of the scarcity and
the morphology of the lesions. Rare typical Lewy bodies
have been reported in the outermost plexus of the gut,
namely the myenteric plexus, which can not be reached
with a routine gastrointestinal biopsy [8, 17, 20]. By con-
trast, the mucosa and the submucosa, which are captured
by the biopsy-forceps, primarily contain thread-like and
dot-like alpha-synuclein deposits in nerve endings, remin-
iscent of the small-sized Lewy neurites observed in the
brain [8, 12, 23, 24]. Such a morphology of staining can
make it difficult to differentiate between LTS and physio-
logical and/or non-specific alpha-synuclein staining in en-
doscopy tissue samples.
The above-mentioned limitations outline the critical
need to develop proper neuronal counterstaining for the
analysis of LTS in gastrointestinal biopsies. Combining
routine colonic biopsies and microdissection techniques,
we have previously shown that collecting whole-mounts
of submucosa and mucosa enable a comprehensive as-
sessment of the neural networks of these two structures
[11, 12]. In such whole mount-preparations, immunohis-
tochemical analysis with a general neuronal marker such
as PGP9.5, NF220 and Hu revealed that a single standard
colonic biopsy contains an average of 150 submucosal
neurons and a dense network of nerve fibers in the mu-
cosa [11, 24]. Although this approach provides outstand-
ing information on the morphology of enteric neurons
and allows the detection of Lewy pathology in most PD
subjects, it nonetheless has several limitations as it has to
be performed quickly following the endoscopic procedure,
requires an experienced technician and is not suitable for
retrospective analysis. It is therefore unlikely that such a
procedure will be used in large-scale multicenter studies
and there is a clearly need for reliable ways to label neur-
onal structures in FFPE gastrointestinal biopsies. Most of
the available studies performed on FFPE blocks did not
use any neuronal markers and relied primarily on morph-
ology to identify the neuronal processes [13, 16, 17]. Only
two studies used S100 staining to exclude a significant
proportion of biopsies from analysis due to the lack or
paucity of nerve fibers [14, 15]. For specificity reason, we
would however not recommend the use of S100 staining
for the detection of the neuronal processes as this protein
is widely expressed by enteric glial cells, which are found
in routine gastrointestinal biopsies [25]. Our preliminary
observation suggests that immunostaining with the pan
neuronal marker PGP9.5 is an efficient screening method
to establish whether the tissue sample contains an ad-
equate number of neuronal structures.
In the current study, 3 out of 4 participating laborator-
ies used antibodies against alpha-synuclein phosphory-
lated at serine 129 to detect LTS. Since the discovery by
Fujiwara and coworkers that this residue was selectively
and extensively phosphorylated in synucleinopathy le-
sions [26], antibodies for phosphorylated alpha-synuclein
have been widely used to label LTS in the central ner-
vous system as well as in peripheral autonomic networks
including the enteric nervous system [3, 9]. Regarding
gastrointestinal biopsies, most of the existing studies
have used phospho-alpha-synuclein rather than total
alpha-synuclein antibodies for the detection of patho-
logical alpha-synuclein. Although some studies reported
that staining with phospho-alpha-synuclein antibodies to
be more extensive to that obtained with total alpha-
synuclein [14, 27], other studies found the opposite
[15, 16]. This may be due to the fact that a small
amount (around 4 %) of alpha-synuclein is physiolo-
gically phosphorylated at serine 129 [26], implying
that phospho-synuclein antibodies can detect physio-
logic non-aggregated protein when no pretreatment is
used. In this context, Visanji et al. recently adapted
the paraffin-embedded tissue (PET) blot method, which
degrades physiologic nonaggregated proteins and has been
demonstrated to have superior sensitivity in detecting
aggregated protein, to the detection of LTS in gastrointes-
tinal samples [16]. Surprisingly, they observed phospho-
alpha-synuclein immunostaining in the colonic mucosa of
11/11 of control subject, despite the use of the PET blot
method. This strongly suggests that non specific staining
occurs in the gastrointestinal mucosa when phospho-
alpha-synuclein antibodies are used, thereby explaining
the lack of specificity observed in our study.
One obvious limitation of our study is the small sam-
ple size of the control group and it is possible that if it
was repeated with more controls, the diagnostic accur-
acy of some of the methods might be higher. Another
limitation was the absence of submucosa, blood vessels
or judge’s scores for most of the slides, and for two of
three control cases, rated for the perivascular staining
morphology produced by the one testing laboratory
(DM). It is possible, if all three controls had been graded
and the staining scores segregated with the appropriate
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diagnosis, that the results for this laboratory may have
been in fact acceptably accurate. Arguing against this
possibility, however, is the low accuracy for this same
morphology as produced by the central laboratory.
Conclusions
In conclusion, although our study has produced results
that are less than definitive but it suggests that the tested
immunohistochemical methods are not adequate for the
prediction of PD in endoscopically obtained gastroinest-
inal biopsies. This failure may be due to the relative rar-
ity of neuronal synucleinopathy in the submucosa of the
colon or to the lack of sensitivity and specificity of the
methods tested. Future studies including more control
subjects along with new staining methods and screening
for neuronal markers are needed.
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